ClinicalTrials.gg
CompletedNCT02954666CardNMH2Updated Jan 20, 2021

Second Study on Cardio-neuromodulation in Humans

An interventional study of radio-frequency ablation in Cardiac Disease, Syncope and Syncope, Vasovagal, sponsored by Imelda Hospital, Bonheiden. Completed at 1 site in Belgium. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2021-01-20.

Primary conditionSick Sinus SyndromeRegistry: Heart DiseasesReclassifiedWhy we changed it
Registry
Heart Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sick Sinus Syndrome
Why
  1. The study's listed conditions name Sick Sinus Syndrome, a narrower term within Heart Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Imelda Hospital, Bonheiden · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
14 Years and older
Sex
All
01

Study summary

Different approaches to cardio-neuroablation (CNA) to treat neurally mediated syncope, sinus node dysfunction, and functional atrioventricular block have been published. Investigators have developed a more limited and specific approach of CNA, called cardio-neuromodulation (CardNM). This treatment is based on a tailored vagolysis of the sinoatrial node through partial ablation of the anterior right ganglionated plexus (ARGP); it is also based on an innovative anatomic strategy. The feasibility of CardNM has already been tested in our center in a limited first study in humans (CardNMH1), with a favorable outcome for the patients involved. The results of CardNMH1 have been submitted for publication. The purpose of this second study of CardNM in humans (CardNMH2) is to collect more procedural and clinical data in well-defined patient groups.

Read the detailed description

This is a phase II A prospective, interventional study. All patients will undergo CardNM. The study will involve eight different steps, from the screening procedure through study completion: screening, enrollment, pharmacological testing, group allocation, preprocedural assessment, procedure, follow-up, study completion.The dedicated study nurse and the PI are responsible for recording all data from the trial on the case report forms (CRFs) and completing the study database. A dedicated independent physician will be responsible for the safety monitoring. The PI will permit inspection of the trial files and the database by national or international official controlling scientific authorities, if required. The PI will review and monitor completed CRFs and the database at regular intervals throughout the trial.

02

Conditions studied

  • Cardiac Disease
  • Syncope
  • Syncope, Vasovagal
  • Sick Sinus Syndrome

Browse trials for

Keywords

  • cardio-neuromodulation
  • cardio-neuroablation
  • ablation
  • ganglionated plexi
  • anterior right ganglionated plexus
  • syncope
03

In context

Sick Sinus Syndrome Reclassified

93 studies on the registry are indexed under Sick Sinus Syndrome; 18 are open to participants now.

This study's enrollment of 50 is below the median of 137 across 62 interventional studies indexed under Sick Sinus Syndrome.

Browse Sick Sinus Syndrome studies →

Lead sponsor

Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Compared within Sick Sinus Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Candidates must meet all of the inclusion criteria required for inclusion in one of the two groups (summarized in Table 2). All of the patients need to have a positive P wave of > 0.5 mm in lead 2. Patients must have had ≥ 1 syncope during the 6 months preceding enrollment and ≥ 2 syncopes in their lifetime except if the last syncope was complicated by an injury or an accident, in which case further waiting for CardNM may be less desirable. Patients \< 18 years must have least 3 syncopes with an interval exceeding 1 month unless 1 syncope was complicated by an injury or an accident.

If a significant rate drop (> 15%) is noted during head-up tilt test (HUT), either isolated or combined with vasoplegia, and associated with syncope or severe presyncope, patients will be eligible for inclusion in group A. If the HUT is negative and a pause > 3 seconds has been documented, patients will be assigned to group B. If both conditions are present, patients will be eligible for inclusion in either group but will be preferentially assigned to group A.

Exclusion criteria

Exclusion Criteria:

Candidates will be excluded if ANY of the following criteria apply (detailed in Table 3):

  • \< 14 years of age;
  • Inability to provide consent;
  • Chronotropic negative medications (excepted in patients with a previous history of atrial fibrillation);
  • 4 g amiodarone intake during the 2 months preceding enrollment;
  • Alternating right bundle branch block (RBBB) and left bundle branch block (LBBB), HV interval > 70 ms;
  • LBBB, bifascicular block (RBBB + left anterior hemiblock [LAHB], RBBB + left posterior hemiblock [LPHB]);
  • PR interval permanently > 240 ms;
  • Permanent AF, PAF or electrical cardioversion during the last 6 months;
  • Valvular or subvalvular aortic stenosis, mitral stenosis;
  • Any unstable medical condition, \< 12 months;
  • Syncopes due a non-cardiac disease (excepted NMS) or advanced neuropathy;
  • Current pregnancy;
  • glaucoma.

Patients with transient atrioventricular conduction disturbances and normal atrioventricular conduction during an exercise test and normal QRS complexes are eligible for this study.

Patients with a high risk of bleeding are eligible, but clopidogrel (75 mg daily, 1 month of treatment) will then be preferred to oral anticoagulants.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Patients with neurally mediated syncope

    Tailored radio-frequency ablation of the ARGP (CardNM).

    Device: radio-frequency ablation

  • Experimental
    Patients with sick sinus syndrome

    Tailored radio-frequency ablation of the ARGP (CardNM).

    Device: radio-frequency ablation

Interventions

  • Deviceradio-frequency ablation

    Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation. The ablation procedure is considered complete when one of the following conditions is fulfilled: P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter.

    Also known as: cardio-neuromodulation, cardio-neuroablation, ARGP

06

What researchers measure

Primary outcomes

  1. freedom from syncope

    Time frame: 12 months

  2. freedom from serious adverse event

    Time frame: 7 days

Secondary outcomes

  1. freedom from pre syncope

    Time frame: 12 months

Other outcomes

  1. quantification of the vagolysis of the sinus node

    The quantification of vagolysis of the sinus node obtained during CardNM will be evaluated by automatic P-P interval measurements during procedure, by ECG derived and standardized P-P interval measurements and by automatical quantification of P-P interval histograms on Holter registrations before procedure and during FU.

    Time frame: procedure, 1,3,6,12 months

07

Study locations

1 site
  • Imeldaziekenhuis
    Bonheiden, Antwerpen 2820, Belgium
08

References and documents

Publications

  • Debruyne P. "Cardio-Neuromodulation" With a Multielectrode Irrigated Catheter: A Potential New Approach for Patients With Cardio-Inhibitory Syncope. J Cardiovasc Electrophysiol. 2016 Sep;27(9):1110-3. doi: 10.1111/jce.13031. Epub 2016 Aug 1. PubMed 27307200 ↗
  • Debruyne P, Rossenbacker T, Janssens L, Collienne C, Ector J, Haemers P, le Polain de Waroux JB, Bazelmans C, Boussy T, Wijns W. Durable Physiological Changes and Decreased Syncope Burden 12 Months After Unifocal Right-Sided Ablation Under Computed Tomographic Guidance in Patients With Neurally Mediated Syncope or Functional Sinus Node Dysfunction. Circ Arrhythm Electrophysiol. 2021 Jun;14(6):e009747. doi: 10.1161/CIRCEP.120.009747. Epub 2021 May 17. PubMed 33999698 ↗
  • Debruyne P, Rossenbacker T, Collienne C, Roosen J, Ector B, Janssens L, Charlier F, Vankelecom B, Dewilde W, Wijns W. Unifocal Right-Sided Ablation Treatment for Neurally Mediated Syncope and Functional Sinus Node Dysfunction Under Computed Tomographic Guidance. Circ Arrhythm Electrophysiol. 2018 Sep;11(9):e006604. doi: 10.1161/CIRCEP.118.006604. PubMed 30354289 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Apr 2020, 39 months.

Of 22 interventional studies with no phase under Sick Sinus Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 47. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 3, 2016
StartActual
Dec 10, 2016
Primary completionActual
Apr 1, 2020
CompletionActual
May 11, 2020
Last update
Jan 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02954666
Lead sponsor
Imelda Hospital, Bonheiden
Responsible party
Philippe Debruyne (Principal investigator (PI), Head of Electrophysiology, Imelda Hospital, Bonheiden) — Principal investigator
First posted
Nov 3, 2016
Start date
Dec 10, 2016
Primary completion
Apr 1, 2020
Completion
May 11, 2020
Last update
Jan 20, 2021

Study contacts

Philippe Debruyne, MD
principal investigator · Imeldahospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion